Orexo appoints Nomination Committee and publishes financial calendar 2014/2015

Prior to the Annual General Meeting 2015, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and votes in the company based on the last known shareholder information.

The Nomination Committee, whose tasks include providing proposals to the General Meeting regarding Chairman of the Meeting, Board members, Chairman of the Board, fees for the board members, any remuneration for committee work, proposal for and fees to the company’s auditor as well as principles for composition of the Nomination Committee, comprises:

  • Eivind Kolding, Novo A/S, also Chairman of the Nomination Committee
  • Björn Odlander, HealthCap
  • Claus Berner Møller, Arbejdsmarkedets Tillaegspension (ATP)
  • Martin Nicklasson, Chairman of the Board of Orexo

The Nomination Committee’s proposals will be presented in the Notice to the Annual General Meeting 2015 and on Orexo’s web site, www.orexo.com.

Shareholders who want to submit proposals to the Nomination Committee, can do this by sending an e-mail to beata.augenblick@orexo.com (subject “Nomination Committee”) or by letter posted to “Orexo’s Nomination Committee”, Orexo AB, P.O. Box 303, SE-751 05 Uppsala, Sweden, by February 13, 2015 at the latest.

The Annual General Meeting 2015 in Orexo will be held on Wednesday, April 15, 2015 at 4:00pm CET in Uppsala. Shareholders who want to have a matter addressed at the Annual General Meeting 2015 must submit such a proposal to the same address as above (subject “Annual General Meeting 2015” for the e-mail and the letter, respectively) by March 4, 2015 at the latest.

Future information reporting dates from Orexo:

Interim Report January – September 2014 October 22, 2014
Year-End Report 2014 January 29, 2015
Publication of the Annual Report Week 13, 2015
Annual General Meeting 2015 April 15, 2015 at 4:00pm CET
Interim Report January – March 2015 April 23, 2015
Interim Report January – June 2015 July 10, 2015
Interim Report January – September 2015 October 22, 2015

For further information, please contact:
Henrik Juuel, EVP and Chief Financial Officer or Beata Augenblick, Investor Relations
Tel: +46 (0)18-780 88 00, E-mail:

About Orexo AB
Orexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery. The company is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for maintenance treatment of opioid dependence, in the United States. The ZUBSOLV sublingual tablet is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, EU and Japan. Orexo AB, with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo AB, please visit www.orexo.com.